New NASH drug shows promise in early trial
NCT ID NCT05338034
First seen May 29, 2026 · Last updated Jun 11, 2026 · Updated 1 time
Summary
This study tested an experimental drug called HPG1860 in 89 adults with NASH, a serious liver disease linked to obesity. Participants received one of three doses of the drug or a placebo for 12 weeks. The main goals were to check safety and see if the drug could reduce liver fat. Results will help decide if larger studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
South Texas Research Institute (STRI)
Texas City, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.